What it is used for

INDICATIONS: Treatment for the following infections when caused by susceptible aerobic organisms: 1 Lower respiratory tract infections. Caused by Strep.pneumoniae, Streptococcus sp. (excluding Enterococci), methicillin sensitive Staph.aureus, H.incluenzae, H.parain fluenzae, Klebsiella sp. (including K.pneumoniae). E.coli, E. aerogenes, P.mirabilis and serratia marcescens. 2 Skin and skin structure infections. Caused by methicillin sensitive Staph.aureus, methicillin sensitive Staph.epidermidis, Streptococcus Group B, Streptococcus group G, Strep.pyogenes, Strep.viridans, Streptococcus sp. (excluding Enterococci), Peptostreptococcus sp.,_(including K.pneumoniae and K.oxytoca), P.mirabilis, M.morganii and S.marcescens. 3 Urinary tract infections (complicated and uncomplicated). Caused by E.coli, P.mirabilis, P.vulgaris, M.morganii and Klebsiella sp. (including K.pneumoniae). Uncomplicated gonorrhoea (cervical/urethral and rectal) Caused by N.gonorrhoeae, including both penicillinase and nonpenicillinase producing strains. 5 Bacterial septicaemia. Caused by Strep.pneumoniae, E.coli and H.influenzae. 6 Bone Infections. Caused by methicillin sensitive Staph.aureus, methicillin sensitive Staph.epidermidis, Streptococcus group B, Strep.pneumoniae., Streptococcus sp._ 7 Joint infections. Caused by methicillin sensitive Staph.aureus, Strep.pneumoniae, Streptococcus sp. (excluding Enterococci), E.coli, P.mirabilis. K.pneumoniae and Enterobacter sp. 8 Meningitis. the initial treatment, as a single agent, of menigitis in children and immunocompetent adults when presumed or proven to be caused by H.influenzae type b, N.meningitidis, Strep.pneumoniae or Enterobacteriaceae pending culture and sensitivity results. 9 Surgical prophylaxis . The preoperarive administraion of a single 1g dose of ceftriaxone may reduce the incidence of postoperative infections in patients undergoing vaginal or abdominal hysterectomy or cholecystectomy in high risk patients, surgical_procedures which are classified as contaminated or potentially contaminated, and patients undergoing coronary artery bypass surgery. Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo controlled trials have been conducted. 10 Susceptibility testing. Before instituting treatement with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing.

How to take it

The way to take this medicine is: Intramuscular. This medicine is given through a needle inserted into the muscle beneath the skin.

• Store below 25 degrees Celsius
• Protect from Moisture
• Protect from Light
• Shelf lifetime is 3 Years.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.

Visual appearance

Clear glass vial containing a white to yellowish powder

Do I need a prescription?

This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine. open tool tip to find out more

Is this medicine subsidised?

This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on July 1, 2019. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.

Pregnant or planning a pregnancy?

For the active ingredient ceftriaxone

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.